Biostax Corp. (BTAX)

0,0360 0,0000 (0,00%) Al cierre: 10:58AM EDT

Biostax Corp.

1317 Edgewater Dr.
Suite 4882
Orlando, FL 32804
United States
888 391 9355
https://www.biostaxcorp.com

Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Ms. Noreen M. Griffin	Founder, Executive VP of Business Development & CEO	111,74k	N/A	1953
Ms. Kelly O'Brien Wilson	President	285,95k	N/A	1971
Mr. Glen A. Farmer M.B.A.	Chief Financial Officer	155,33k	N/A	1969
Ms. Cynthia Douglas	Company Secretary	N/A	N/A	1973
Dr. Joseph M. Fortunak	Vice President of Global Research & Development and Chemical Development	N/A	N/A	1955

Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Biostax Corp. operates as a biopharmaceutical company that acquires, develops, and commercializes pharmaceutical and biotechnology products. Its lead investigational drug candidate Lodonal, an once-a-day immune system regulator for the management of human immunodeficiency virus and acquired immune deficiency syndrome (HIV/AIDS). Its programs also include Global Telehealth platform; Medtech asset, an early development stage program that uses blockchain and smart contracts to manage and secure prescriptions and electronic health records; JKB-122, an investigational small molecule, long-acting toll-like receptor 4 (TLR4) antagonist developed for autoimmune hepatitis, nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH); and Low Dose Naltrexone, a compound formula that is purported to provide immune-modulating benefits that include cancer, pain, autoimmune, and anti-aging. The company also develops programs for the treatment of hyperphosphatemia. It has a licensing agreement with Cytocom Inc. The company was formerly known as Immune Therapeutics, Inc. and changed its name to Biostax Corp. in October 2023. Biostax Corp. is headquartered in Orlando, Florida.

Gobierno corporativo

El ISS Governance QualityScore de Biostax Corp., a día N/A, es N/A. Las puntuaciones base son Auditoría: N/A; Tablero: N/A; Derechos de los accionistas: N/A; Compensación: N/A.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.